Non-small cell lung cancer (NSCLC)
MK-1084-007 / KANDLELIT-007
MK1084 in combination with Subcutaneous Pembrolizumab with berahyaluronidase alfa (MK3475A) versus Pembrolizumab in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC
Trial overview
Clinical Area
Medical Oncology
Disease
Non-small cell lung cancer (NSCLC)
Disease site
Lung & bronchus
Study Phase
III
Trial Identifiers
Registration number: NCT07190248
GenesisCare Location(s)
Principal Investigator(s)